Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus
The new quinolone garenoxacin (BMS-284756), which lacks a C-6 fluorine, was examined for its ability to block the growth of Staphylococcus aureus. Measurement of the MIC and the mutant prevention concentration (MPC) revealed that garenoxacin was 20-fold more potent than ciprofloxacin for a variety o...
Сохранить в:
| Опубликовано в:: | Antimicrob Agents Chemother |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society for Microbiology (ASM)
2003
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC149307/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12604537/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.3.1023-1027.2003 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|
